<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In our previous phase I study of temozolomide in patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, temozolomide was well tolerated and demonstrated significant anti-leukemic activity </plain></SENT>
<SENT sid="1" pm="."><plain>The maximum tolerated dose was 200 mg/m2/d for 7 days, repeated approximately every 5-6 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>In the current study, we evaluated the same dose of temozolomide in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Fourteen patients received 19 courses of temozolomide </plain></SENT>
<SENT sid="4" pm="."><plain>The median age was 71 years </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, treatment was poorly tolerated with patients requiring admission in 9 of 19 courses </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicity included worsening cytopenias, neutropenic <z:hpo ids='HP_0001945'>fever</z:hpo>, and exacerbation of <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e>, the latter due to worsening <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>An unusual finding was the development of leukocytoclastic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> in 4 patients </plain></SENT>
<SENT sid="8" pm="."><plain>There were no formal responses to therapy </plain></SENT>
<SENT sid="9" pm="."><plain>The current schedule of temozolomide is not efficacious in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
</text></document>